ArticleMedical molecular morphology2026
Clinicopathological significance and prognostic value of the MSI1/MTFR2 axis in clear cell renal cell carcinoma: linking stemness and mitochondrial dynamics.
Article in Medical molecular morphology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) carries a high risk of recurrence, necessitating reliable prognostic biomarkers. This study evaluated the immunohistochemical expression, clinicopathological significance, and prognostic value of Musashi-1 (MSI1) and MTFR2 in ccRCC. Expression of MSI1 and MTFR2 was evaluated by immunohistochemistry in 124 ccRCC cases and paired non-neoplastic renal tissues. Associations with clinicopathological parameters and prognostic scoring models (SSIGN, UISS, SIS) were assessed, applying False Discovery Rate (FDR) procedures for multiple hypothesis testing. Progression-free survival (PFS) and disease-free survival (DFS) were analyzed using Kaplan-Meier curves, log-rank tests, and multivariate Cox regression models with multicollinearity diagnostics (VIF). Both MSI1 and MTFR2 were significantly upregulated in ccRCC compared to normal tissues (p < 0.001) and positively correlated with each other (r = 0.676, p < 0.001). High expression of either marker was significantly associated with adverse baseline features (larger tumour size, higher WHO/ISUP grade, advanced T-stage; q < 0.05) and higher-risk SSIGN, UISS, and SIS scores. Elevated MSI1 and MTFR2 predicted significantly shorter PFS and DFS (p < 0.001). Multivariate analysis confirmed T-stage, WHO/ISUP grade, MSI1, and MTFR2 as independent prognostic factors for PFS and DFS. The MSI1/MTFR2 axis represents strong independent prognostic signature in ccRCC and may enhance risk stratification while highlighting potential therapeutic targets.
Indexed as
Identifiers
42762315What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.